The FDA has withdrawn approval of the lymphoma drug umbralisib (Ukoniq) due to a "possible increased risk of death."
Umbralisib received accelerated approval in February 2021.
The FDA posted a statement urging healthcare professionals to stop prescribing Ukoniq to switch patients to alternative treatments.
The organization also urged patients currently taking Ukoniq of the increased risk of death seen in the clinical trial.
Another lousy drug rushed to market without adequate safety testing that harmed and killed people.